Progestins inhibit the growth of MDA-MB-231 cells transfected with progesterone receptor complementary DNA

Clinical Cancer Research

Volumn 5, Issue 2, 1999, Pages 395-403

  Lin, Valerie C L ^a,b   Ng, Eng Hen ^a   Aw, Swee Eng ^b   Tan, Michelle G K ^b   Ng, Esther H L ^a   Chan, Vivian S W ^b   Ho, Gay Hui ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b MINISTRY OF HEALTH   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

16ALPHA ETHYL 21 HYDROXY 19 NORPREGN 4 ENE 3,20 DIONE; COMPLEMENTARY DNA; GESTAGEN; MEDROXYPROGESTERONE ACETATE; MIFEPRISTONE; ONAPRISTONE; PROGESTERONE RECEPTOR; PROMEGESTONE;

ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DNA TRANSFECTION; DRUG EFFECT; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BREAST NEOPLASMS; CELL CYCLE; CELL DIVISION; DNA; DNA, COMPLEMENTARY; ESTRADIOL; HUMANS; PROGESTERONE; PROGESTINS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0345313655     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Sutherland, R. L., Hall, R. E., Pang, G. Y. N., Musgrove, E. A., and Clarke, C. L. Effect of medroxyprogesterone acetate on proliferation and cell cycle kinetics in human mammary carcinoma cells. Cancer Res., 48: 5084-5091, 1988.
2. Van der Burg, B., Kalhoven, E., Isbrücker, L., and de Laat, S. W. Effects of progestins on the proliferation of estrogen-dependent human breast cancer cells under growth factor-defined conditions. J. Steriod Biochem. Mol. Biol., 42: 457-465, 1992.
3. Schoonen, W. G. E. J., Joosten, J. W. H., and Kloosterboer, H. J. Effects of two classes of progestagens, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells: II. T47D cell lines. J. Steroid Biochem. Mo. Biol., 55: 439-444, 1995.
4. Moore, M. R., Hathaway, L. D., and Bircher, J. A. Progestin stimulation of thymidine kinase in the human breast cancer cell line T47D. Biochim. Biophys. Acta., 1096: 170-174, 1991.
5. Jeng, M-H., Parker, C. J., and Jordan, V. C. Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation. Cancer Res., 52: 6539-6546. 1992.
6. Kalkhoven, E., Kwakkenbos-Isbrücker, L., de Laat, S. W., Van der Saag, P. T., and Van der Burg, B. Synthetic progestins induce proliferation of breast tumor cell lines via the progesterone or estrogen receptor. Mol. Cell. Endocrinol., 102: 45-52, 1994.
7. Classen, S., Possinger, K., Pelka-Fleischer, R., and Wilmanns, W. Effect of onapristone and medroxyprogesterone acetate on the proliferation and hormone receptor concentration of human breast cancer cells. J. Steriod Biochem. Mol. Biol., 45: 315-319, 1993.
8. Clarke, C. L., and Sutherland, R. L. Progestin regulation of cellular proliferation. Endocr. Rev., 11: 266-301, 1990.
9. Botella, J., Duranti, E., Duc, I., Cognet, A. M., Delansorne, R., and Paris, J. Inhibition by nomegestrol acetate and other synthetic progestins on proliferation and progesterone receptor content of T47-D human breast cancer cells. J. Steriod Biochem. Mol. Biol., 50: 41-47, 1994.
10. Schoonen, W. G. E. J., Joosten, J. W. H., and Kloosterboer, H. J. Effects of two classes of progestagens, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells: I. MCF-7 cell lines. J. Steroid Biochem. Mol. Biol., 55: 423-437, 1995.
11. Dauvois, S., Simard, J., Dumont, M., Haagensen, D. E., and Labrie, F. Opposite effects of estrogen and the progestin R5020 on cell proliferation and GCDFP-15 expression in ZR-75-1 human breast cancer cells. Mol. Cell. Endocrinol., 73: 171-178, 1990.
12. Hissom, J. R., and Moore, M. R. Progestin effects on growth in the human breast cancer cell line T-47D:possible therapeutic implications. Biochem. Biophys. Res. Commun., 145: 706-711, 1987.
13. Cappeletti, V., Miodini, P., Fioravanti, L., and Difronzo, G. Effect of progestin treatment on estradiol and growth factor-stimulated breast cancer cell lines. Anticancer Res., 15: 2551-2555, 1995.
14. Byrne, M. J., Gebski, V., Forbes, J., Tattersall, M. H. N., Simes, R. J., Coates, A. S., Dewar, J., Lunn, M., Flower, C., Gill, P. G., and Stewart, J. Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. J. Clin. Oncol., 15.-3141-3148, 1997.
15. Pannuti, F., Martoni, A., Piana, E., and Guaraldi, M. Progestins in breast cancer. Adv. Clin. Oncol., 3: 207-222, 1988.
16. Hultborn, R., Johanssonterje, I., Bergh, J., Glas, U., Hallsten, L., Hatschek, T., Holmberg, E., Idestrom, K., Norberg, B., Ranstam, J., Soderberg, M., and Wallgren, U. B. Second-line endocrine treatment of advanced breast cancer: a randomized cross-over study of medroxy-progesterone acetate and aminoglutethimide. Acta Oncol., 35: 75, 1996.
17. Shi, Y. E., Liu, Y. L. E., Lippman, M. E., and Dickson, R. B. Progestins and antiprogestins in mammary tumour growth and metastasis. Hum. Reprod. (Oxf.), 9: 162-173, 1994.
18. Michna, H., Nishino, Y., Neef, G., McGuire, W. L., and Schneider, M. R. Progesterone antagonists: tumor-inhibiting potential and mechanism of action. J. Steroid Biochem. Mol. Biol., 41: 339-348, 1992.
19. Klijn, J. G. M., Setyono-Han, B., Sander, H. J., Lamberts, S. W. J., de long, F. H., Deckers, G. H., and Foekens, J. A. Pre-clinical and clinical treatment of breast cancer with antiprogestins. Hum. Reprod., 9: 181-189, 1994.
20. Druege, P. M., Klein, H. L., Green, S., Stack, G., Chambon, P., and Ryffel, G. U. Introduction of estrogen-responsiveness into mammalian cell lines. Nucleic Acids Res., 14: 9329-9337, 1986.
21. Graham, J. D., Roman, S. D., MaGowan, E., Sutherland, R. L., and Clarke, C. L. Preferential stimulation of human progesterone receptor B expression by estrogen in T47-D human breast cancer cells. J. Biol. Chem., 270: 30693-30700, 1995.
22. Shyamala, G. Oestrogenic sensitivity and its resistance in normal murine mammary glands. Prog. Cancer Res. Ther., 31: 293-303, 1984.
23. Kaneko, K. J., Gelinas, C., and Gorski, J. Activation of the silent progesterone receptor gene by ectopic expression of estrogen receptors in a rat fibroblast cell line. Biochemistry, 32: 8348-8359, 1993.
24. Otto, A. M. A one minute pulse of estradiol to MCF-7 breast cancer cells changes estrogen receptor binding properties and commits cells to induce estrogenic responses. J. Steroid Biochem. Mol. Biol., 54: 39-46, 1995.
25. Dotzlaw, H., Leyque, E., Watson, P. H., and Murphy, L. C. Expression of estrogen receptor-β in human breast tumors. J. Clin. Endocrinol. Metab., 82: 2371-2374, 1997.
26. McGuire, W. L. Hormones receptors: their role in predicting prognosis and response to endocrine therapy. Semin. Oncol., 5: 428-433, 1978.
27. Kastner, P., Bocquel, M-T, Turcotte, B., Gamier, J-M, Horwitz, K. B., Chambon, P., and Gronemeyer, H. Transient expression of human and chicken progesterone receptors does not support alternative translational initiation from a single mRNA as the mechanism generating two receptor isoforms. J. Biol. Chem., 265: 12163-12167. 1990.
28. Vindelov, L. L., Christensen, I. J., Nissen, N. I. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry, 3: 323-327, 1983.
29. Vignon, F., Bardon, S., Chalnos, D., and Rockefort, H. Antiestrogenic effect of R5020, a synthetic progestin in human breast cancer cells in culture. Clin. Endocrinol. Metab., 56: 1124-1130, 1983.
30. Musgrove, E. A., Lee, C. S., and Sutherland, R. L. Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor-α. Mo. Cell. Biol., 11: 5032-5043, 1991.
31. kip1. Mol. Endocrinol., 77: 1593-1607, 1997.
32. Sartorius, C. A., Groshong, S. D., Miller, L. A., Powell, R. L., Tung, L., Takimoto, G. S., and Horwitz, K. B. New T47D breast cancer cell lines for the independent study of progesterone B-and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP. Cancer Res, 54: 3868-3877, 1994.
33. Horwitz, K. B., Tung, L., and Takimoto, G. S. Novel mechanisms of antiprogestin action. J. Steroid Biochem. Mol. Biol., 53: 9-17, 1995.
34. Edwards, D. P., Altmann, M., DeMarzo, A., Zhang, Y., Weigel, N. L., and Beck, C. A. Progesterone receptor and the mechanism of action of progesterone antagonists. J. Steroid Biochem. Mol. Biol., 53: 449-458, 1995.
35. Nordeen, S. K., Bona, B. J., and Moyer, M. L. Latent agonist activity of the steroid antagonist, RU486, is unmasked in cells treated with activators of protein kinase A. Mol. Endocrinol., 7: 731-742, 1993.
36. Jackson, T. A., Richer, J. K., Bain, D. L., Takimoto, G. S., Tung, L., and Horwitz, K. B. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol. Endocrinol., 11: 693-705, 1997.
37. Osborne, C. K., and Fuqua, S. A. W. Mechanisms of tamoxifen resistance. Breast Cancer Res. Treat., 32: 49-55, 1994.
38. Rove, R. R. Tamoxifen therapy in primary breast cancer: biology, efficacy and side effects. J. Clin. Oncol., 7: 803-815, 1989.
39. Ruppert, J. M., Wright, M., Rosenfeld, M., Grushcow, J., Bilbao, G., Curiel, D. T., and Strong, T. V. Gene therapy strategies for carcinoma of the breast. Breast Cancer Res. Treat., 44: 93-114, 1997.
40. Fuqua, S. A. Where is the lesion in hormone-independent breast cancer? J. Natl. Cancer Inst., 84: 554-555, 1992.
41. Levenson, A. S., and Jordan, V. C. Transfection of human estrogen receptor (ER) cDNA into ER-negative mammalian cell lines. J. Steroid Biochem. Mol. Biol., 57: 229-239, 1994.
42. Jiang, S-Y, and Jordon, V. C. Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J Natl. Cancer Inst., 84: 580-591, 1992.